Sexual Health · Peptide

Kisspeptin

Category: Sexual Health Last updated 2026-06-19

Kisspeptin at a glance

Kisspeptin is a hypothalamic peptide that activates the gonadotropin-releasing hormone (GnRH) system upstream of the entire reproductive axis. Studied for hypothalamic amenorrhea, hypogonadism, and libido. Mechanism: Hypothalamic neuropeptide. Typical route: Subcutaneous, intranasal. FDA status: Not FDA-approved as a finished drug product. Used in clinical research and dispensed by specialty compounding pharmacies for off-label hypogonadism, hypothalamic amenorrhea, and libido protocols.

Drug classHypothalamic neuropeptide

Half-life~20-30 minutes

RouteSubcutaneous, intranasal

Common dosing50-200 mcg, 2-3x/week

FDA statusNot approved

Available throughCompounding pharmacies

Mechanism of action

Kisspeptin activates the KISS1R receptor on GnRH neurons in the hypothalamus, stimulating pulsatile GnRH release. GnRH then drives pituitary LH/FSH release, which in turn stimulates testicular testosterone or ovarian estradiol production. Kisspeptin therefore acts upstream of testosterone or HCG protocols.

Dosing reference

Subcutaneous: 50-200 mcg, two to three times weekly. Some protocols dose intranasally at higher amounts. Optimal dosing for sexual-health applications is not standardized.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved as a finished drug product. Used in clinical research and dispensed by specialty compounding pharmacies for off-label hypogonadism, hypothalamic amenorrhea, and libido protocols.

U.S. telehealth providers that work with Kisspeptin

#1 of 3

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is covered in our editorial directory and works with peptides in the sexual-health category.

Read review →

#2 of 3

Maximus

76/100v3.0 six-pillar rubric

Starting at $149/mo. Maximus is covered in our editorial directory and works with peptides in the sexual-health category.

Read review →

#3 of 3

Hone Health

80/100v3.0 six-pillar rubric

Starting at $149/mo. Hone Health is covered in our editorial directory and works with peptides in the sexual-health category.

Read review →

Related sexual-health peptides

Browse the full Sexual Health category →

Frequently asked questions about Kisspeptin

How does kisspeptin differ from testosterone replacement?

Testosterone replacement suppresses the body's own hormone production. Kisspeptin activates the body's natural GnRH-LH-testosterone axis, preserving (or restoring) endogenous production rather than replacing it.

Can kisspeptin be used during testosterone replacement?

Combining kisspeptin with exogenous testosterone may not produce additive effects; testosterone replacement suppresses the upstream HPG axis. Kisspeptin is most useful where preserving endogenous production matters (fertility, post-cycle therapy, hypothalamic amenorrhea).

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing